Doxorubicin Induced Cardiomyopathy Clinical Trial
Official title:
Role of Statin Therapy in Prevention of Anthracycline-Induced Cardiotoxicity
This study aims at evaluating the role of Atorvastatin in prevention of Anthracycline induced cardiotoxicity
The study participants are female patients with breast cancer receiving Anthracycline based chemotherapy. They will be divided into 2 groups , the first group will receive 40 mg oral atorvastatin through out the study , while the other group will receive a placebo. Full echocardiographic study including 3D echocardiography will be done to all patients before starting their chemotherapy and after 6 months. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT02677714 -
99mTc-rhAnnexin V-128 Imaging and Cardiotoxicity in Patients With Early Breast Cancer
|
Phase 2 | |
| Completed |
NCT02796365 -
Prevention Using Exercise Rehabilitation to Offset Cardiac Toxicities Induced Via Chemotherapy
|
N/A | |
| Not yet recruiting |
NCT06427226 -
Evaluation of the Possible Safety and Efficacy of Dapagliflozin in the Prophylaxis of Doxorubicin-Induced Cardiotoxicity
|
Phase 2 | |
| Completed |
NCT03000036 -
Doxorubicin-associated Cardiac Remodeling Followed by CMR in Breast Cancer Patients
|
N/A | |
| Recruiting |
NCT04461223 -
Evaluation of Myocardial Injury After Anthracycline Chemotherapy in Osteosarcoma Patients Using CMR
|
||
| Recruiting |
NCT06092606 -
A Multicenter Clinical Trial on DH001 Tablets in the Prevention of Doxorubicin-induced Cardiotoxicity in Cancer Patients
|
Phase 2 | |
| Not yet recruiting |
NCT05731375 -
Mitochondrial dysfUnction: a Key Player in Doxorubicin-induced Skeletal and Cardiac muscLE Damage
|